CJC-1295 news and clinical trials

Researchers developed an ELISA method to detect the peptide CJC-1295 in equine plasma at concentrations as low as 12.5 pg/mL. The assay was validated using blood samples from thoroughbred racehorses administered 10 mg of the peptide.

A narrative review of 76 studies on peptide use in urology and sexual medicine found that while some agents like Bremelanotide and Tesamorelin have clinical backing, many others like CJC-1295 remain unvalidated and accessible only through unregulated markets.

A scoping review concluded that claims regarding peptide supplements for musculoskeletal recovery remain unsubstantiated by current human trials. Authors warned of potential risks including cardiovascular complications.

A review of peptides modulating the GH-IGF-1 axis highlights the significant gap between clinical evidence and unregulated self-administration protocols. Clinicians are advised to recognize potential adverse effects like endocrine disturbances, fluid retention, and metabolic issues.

A JBJS Reviews article summarizing injectable peptides in sports medicine concluded that these agents remain experimental, with clinical use limited to approved metabolic agents and rigorous research protocols due to uncertain safety and efficacy.

New review in Frontiers in aging: Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Researchers published a review of approved and unapproved peptide therapies used in sports medicine. They found that while unapproved peptides often show potential for tissue repair in animal models, human safety data remain scarce and carry a risk of serious harm.

A critical review of peptide use in sports concludes that while peptides are marketed as safer alternatives to steroids for bodybuilding, long-term safety data is lacking and the unregulated supply chain poses significant health risks. Evidence for performance enhancement is limited.

A review published in the Journal of the American Academy of Orthopaedic Surgeons analyzed the use of therapeutic peptides in orthopaedics. The authors noted that while peptides show promise in preclinical models for tissue regeneration, there is currently a lack of clinical trials.

A narrative review evaluated evidence for injectable peptide therapy in orthopaedic and sports medicine. The authors concluded that current clinical data remain limited or unvalidated for peptides like BPC 157 and others, necessitating further research before clinical use.

Researchers developed and validated a nano-LC quadrupole/orbitrap mass spectrometry method to detect growth hormone-releasing hormone and analogs like sermorelin and CJC-1295 in urine. The method achieved limits of detection at or below 0.5 ng/mL, meeting WADA anti-doping testing requirements.